# Icsm Avoid Tt Metastatic

> Contraindicates testosterone therapy in men with metastatic prostate cancer because of insufficient safety data and risk of rapid progression. Triggers when a patient has metastatic disease and low testosterone and the clinician wonders "can I use testosterone here?" or "is testosterone therapy appropriate in metastatic PCa?"

- Skill: `dromlakhani/icsm-avoid-tt-metastatic` (Agent Skill)
- Install (CLI): `npx skillmds@latest add dromlakhani/icsm-avoid-tt-metastatic`
- Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/icsm-avoid-tt-metastatic/raw
- Safety review: pending (external: skill-scanner PASS, skillspector PASS)
- Works with: Claude Code, Claude.ai, OpenAI Codex
- Category: Coding & Dev Tools
- Author: dromlakhani (https://skillmd.com/u/dromlakhani)
- Updated: 2026-09-08
- Page: https://skillmd.com/skills/dromlakhani/icsm-avoid-tt-metastatic

---


# Avoid testosterone therapy in metastatic prostate cancer

## STEP 1 — Gather Information
Confirm prostate cancer staging, serum total testosterone (morning fasting), hypogonadism symptoms, PSA, and imaging (bone scan/CT/MRI).  
**Action:** Determine if metastatic prostate cancer is present.

## STEP 2 — Rule In / Rule Out
If metastatic prostate cancer is confirmed → rule out testosterone therapy (contraindicated).  
If not metastatic → proceed to evaluate for testosterone therapy per other Table 6 categories.  
**Action:** Apply the metastatic PCa fork to decide next steps.

## STEP 3 — Classify or Stratify
Classify metastatic PCa as castration‑sensitive or castration‑resistant; note that testosterone therapy remains contraindicated in both per ICSM 2024 evidence level 4.  
**Action:** Recognize that hormone sensitivity does not alter the contraindication.

## STEP 4 — Decide
Do not initiate testosterone therapy; continue androgen deprivation therapy and address hypogonadism symptoms with lifestyle measures, treat comorbidities, or consider non‑hormonal alternatives after shared decision‑making.  
**Action:** Withhold testosterone therapy and implement symptom‑focused care.

## Clinical Guardrails / Mimics / Pitfalls
Do not use testosterone therapy as a therapeutic trial in metastatic PCa; avoid confusing metastatic disease with biochemical recurrence or localized PCa where TTh may be considered; do not rely on low testosterone alone without confirming metastatic status; be aware that initiating TTh may accelerate progression despite lack of increased PCa incidence in non‑metastatic populations.

## Concrete Clinical Example
A 68‑year‑old man with metastatic prostate cancer to spine, on ADT, presents with fatigue and low libido; total testosterone is 9 nmol/L. The clinician asks whether to start testosterone therapy. Per ICSM 2024 guideline, testosterone therapy is contraindicated in metastatic PCa due to insufficient safety data and risk of rapid progression. Decision: Withhold testosterone therapy, continue ADT, evaluate for anemia or depression, and initiate an exercise program.

**Source:** Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024), International Society for Sexual Medicine, 2025, https://doi.org/10.1093/sxmrev/qeaf036